Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 17 and set a price target of ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

As of Dec. 4, there's no reason for it to be that confident, as Lilly took the initiative to run a direct comparison study, and the preliminary results do not appear to favor Novo Nordisk whatsoever.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

Novo Nordisk's (NVO) GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...